Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma
This study examined the association between hector battifora mesothelial antigen-1 (HBME-1) expression and papillary thyroid carcinoma (PTC). A total of 206 patients were enrolled in the current study including 96 PTC patients and 110 patients with benign thyroid nodules (BTN). Immunohistochemistry (Envision) were performed to assess the expression of HBME-1. Receiver operating characteristic curve (ROC) curves were applied to evaluate the diagnostic tumor node metastasis (TNM) value of HBME-1. Specimens from 96 patients with PTC and 110 patients with BTC were reviewed. HBME-1 was positively immunostained in PTC tissue, which was significantly higher than that in BTN tissues (77.1 vs. 5.77 %, P < 0.05). Immunohistochemistry also identified that HBME-1 expression did not show any statistically significant differences based on gender, age, tumor size, TNM stage, and lymph node metastasis (P > 0.05). Importantly, HBME-1 expression was correlated with infiltration levels and differential levels in PTC (both P < 0.05). HBME-1 was found to have high sensitivity (94.5 %) and specificity (77.08 %) for PTC diagnosis. Moreover, HBME-1 had a high specificity (83.33 %) at identifying the differential levels of PTC, but a low sensitivity (22.92 %). The sensitivity and specificity of HBME-1 identifying the infiltration levels of PTC were, respectively, 72.70 and 72.00 %. HBME-1 was highly expressed in PTC tissues, and HBME-1 can serve as a potential biomarker in the diagnosis of PTC.
KeywordsHBME-1 Papillary thyroid carcinoma Immunohistochemistry ROC curve Sensitivity Specificity
We would like to acknowledge the reviewers for their helpful comments on this paper.
Compliance with ethical standards
Conflict of interest
- 23.Ohori NP, Wolfe J, Hodak SP, LeBeau SO, Yip L, Carty SE, et al. "Colloid-rich" follicular neoplasm/suspicious for follicular neoplasm thyroid fine-needle aspiration specimens: cytologic, histologic, and molecular basis for considering an alternate view. Cancer Cytopathology. 2013;121(12):718–28.CrossRefPubMedGoogle Scholar
- 25.Lansoy-Kuhn C, Picquenot JM, Edet-Sanson A, Mechken F, Laberge-Le Couteulx S, Cornic M, et al. Relationship between the immunohistochemistry of the primary tumour and 18f-fdg-pet/ct at recurrence in patients with well-differentiated thyroid carcinoma. Nucl Med Commun. 2013;34(4):340–6.CrossRefPubMedGoogle Scholar
- 31.Nechifor-Boila A, Borda A, Sassolas G, Hafdi-Nejjari Z, Borson-Chazot F, Lifante JC, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using hbme-1 and cd56. Pathol Res Pract. 2013;209(9):585–92.CrossRefPubMedGoogle Scholar